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Abstract
Background: Naturally occurring gastrointestinal disease is an important cause of acute hypoproteinemia in adult
horses and hydroxyethyl starch colloid fluid treatment is a component of supportive care in these cases to
improve plasma volume and maintain colloid osmotic pressure (COP). The objectives of the present study were to
compare 2 formulations of high molecular weight hydroxyethyl starch and their relative effect on COP, acid-base
status, and survival of horses with acute hypoproteinemia secondary to gastrointestinal disease.
Methods: Twenty adult horses, ≥ 1 year of age, were prospectively enrolled, with informed client consent, if they
developed acute hypoproteinemia, defined as a plasma total protein <5.0 g/dL or albumin <2.2 g/dL during
hospitalization while undergoing treatment for gastrointestinal disease. Horses were randomly assigned to receive a
rapid infusion of either 6% hydroxyethyl starch in 0.9% saline or 6% hydroxyethyl starch in lactated ringers solution
at a dose of 10ml/kg. Venous blood gas analysis, COP, and PCV were evaluated before and after colloid
administration.
Results: For both groups, average COP prior to treatment was 11.0 mmHg (9.7 – 12.2 mmHg) and post colloid
treatment was 13.2 mmHg (12.0 -14.7 mmHg) [Normal range 18 – 22 mmHg]. COP was significantly increased with
colloid treatment (p<0.001) but this increase was not significantly different between treatment groups. Venous pH
did not change significantly with treatment. Twelve horses survived to hospital discharge and survival did not differ
significantly between treatment groups.
Conclusions: Post-treatment COP improved approximately 20% regardless of the formulation used, however,
values did not reach the normal range of COP observed in healthy horses. Acid-base parameters were not
significantly impacted by either treatment. Further study is needed to determine how these two products compare
with regards to other outcome measures. Evaluation of the relative effects of colloid formulation in horses with
clinical disease is a future area of interest.
Background
Naturally occurring gastrointestinal disease is an impor-
tant cause of acute hypoproteinemia in adult horses.
Acute hypoproteinemia lowers colloid osmotic pressure
(COP) and can result in negative sequellae, such as
decreased circulating plasma volume, increased extracel-
lular fluid accumulation, and impaired tissue oxygen
delivery contributing to multiorgan failure [1,2]. Low
COP increases risk of death in critical illness without
intervention, therefore colloid fluid treatment is a com-
ponent of supportive care in these cases [3]. Colloid
fluids contain osmotically active macromolecules that are
retained in the vasculature. Thus, colloids act to expand
plasma volume by maintaining COP. Maintaining COP
within normal ranges limits morbidity of disease by
decreasing tissue edema and resultant organ dysfunction.
Colloids used in horses include biologics such as plasma
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and whole blood, and synthetic colloids, such as hydro-
xyethyl starch, pentastarch, and dextrans [1]. Hydro-
xyethyl starch is the most commonly used colloid in
adult horses [1].
Hydroxyethyl starches are commonly selected due to
low cost, long shelf life, and avoidance of the use of bio-
logic agents. Acidosis occurs following hydroxyethyl
starch solution administration in people due to both
dilution and hyperchloremia, and is less likely to occur
when the starch diluent is lactated ringers versus saline
[4,5]. Hydroxyethyl starch solutions are associated with
increased mortality and severe renal injury when used in
critically ill adult humans including those with sepsis,
and excessive bleeding in humans undgergoing open
heart surgery and cardiopulmonary bypass [6]. This has
resulted in a recommendations for human health pro-
fessionals to not use hydroxyethyl starch solutions in
critically ill adults, patients with pre-existing renal dys-
function, patients with signs of renal injury, patients
with coagulopathy associated with cardiopulmonary
bypass, and patients with severe liver disease and to
monitor renal and hepatic function testing following
administration [6].
Artificial colloid formulation may impact outcomes
due to efficacy or side effects, and this has not been
evaluated in horses with clinical disease. Information on
the anticipated effect of colloidal formulations on COP
and survival is not currently available for veterinarians
providing primary care to critical equine patients. To
this end, a preliminary randomized prospective clinical
trial was conducted to compare 2 formulations of high
molecular weight hydroxyethyl starch and their relative
effect on colloid osmotic pressure, acid-base status, in-
hospital complications, and survival. We hypothesized
that intravenous hydroxyethyl starch colloid supplemen-
tation would raise the COP in horses with low protein
secondary to gastrointestinal disease, regardless of the
formulation used. Further, we anticipated that hydro-
xyethyl starch in lactated ringers solution would be less
commonly associated with acidosis than hydroxyethyl
starch in saline solution.
Methods
The experimental protocol was reviewed and approved
by the Institutional Animal Care and Use Committee
(#08-143A-01). Adult horses, ≥ 1 year of age, were pro-
spectively enrolled, with informed client consent, if they
developed acute hypoproteinemia, defined as a plasma
total protein <5.0 g/dL measured by refractometry or
albumin <2.2 g/dL measured by bromcresol green
photometric method (Cobas 510 Chemistry Analyzer,
Roche Diagnostics Corporation, Indianapolis, IN) during
hospitalization while undergoing treatment for gastroin-
testinal disease. Signalment, primary clinical diagnosis,
interval between hospital admission and randomization,
and pre-treatment level of protein or albumin as treat-
ment trigger were recorded. Horses were assigned
at random to one of two treatment groups. Horses in
group 1 (n=10) were treated with 10 mL/kg of 6%
hydroxyethyl starch in 0.9% saline (Hetastarch, Abbott
Laboratories, Chicago, IL, USA). Horses in group 2
(n=10) were treated with 10 mL/kg of 6% hydroxyethyl
starch in lactated ringers solution (Hextend, Abbott
Laboratories, Chicago, IL, USA). Both hydroxyethyl
starch products had an average molecular weight of 670
kD, with a range of 450 to 800 kD, 0.75 molar substitu-
tion, and 1:20 degree of branching, with one a-1,6
branch for every 20 glucose monomer units. Colloid
products were administered via jugular intravenous
catheter with an infusion pump at 200 mL/minute and
no other medications or intravenous fluid therapies
were administered simultaneously. Colloid osmotic pres-
sure (Wescor 4420 Colloid Osmometer, Salt Lake City,
UT, USA), venous blood gas (ABL2000 Blood Gas Ana-
lyzer, Radiometer, Copenhagen, Denmark), and packed
cell volume (PCV) were evaluated before and immedi-
ately following colloid administration. Treatments
assigned by the primary clinician were unrestricted.
Complications arising from the primary disease or from
independent causes, as indicated by the clinician of
record, that developed during hospitalization were
recorded in all horses. Short term survival was defined
as survival to hospital discharge.
All continuous variables underwent Shapiro-Wilk ana-
lysis for normality. As variables were normally distribu-
ted, continuous data were reported as mean and 95%
confidence interval. A paired t test was used to evaluate
changes in COP pre- and post-colloid administration in
both groups. A two sample t test was used to assess dif-
ferences between groups in COP change following colloid
administration. Fisher’s Exact test was used to compare
mortality and complications between groups. Level of
significance for all comparisons was P<0.05. Analysis was
conducted using commercially available software (Stata-
Corp, College Station, TX, USA).
Results
Treatment group 1 was composed of 5 geldings, 4 intact
mares, and 1 ovariectomized mare, with 4 American
Quarter Horses, 3 Thoroughbreds, and one each Arabian,
American Paint Horse, and Friesian. Gastrointestinal dis-
ease diagnoses in treatment group 1 included primary coli-
tis (n=7) and colitis following surgical correction of large
colon volvulus (n=3), and mean interval between admis-
sion and colloid treatment was 23 hours. Treatment group
2 was composed of 4 geldings, 4 intact mares, and 2 stal-
lions, with 4 American Quarter Horses and one each Ara-
bian, American Paint Horse, Oldenburg, Standardbred,
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Thoroughbred, and mixed breed horse. Gastrointestinal
disease diagnoses in treatment group 2 included primary
colitis (n=3), colitis following surgical correction of large
colon volvulus (n=4), proximal enteritis (1), and peritonitis
secondary to perforating foreign body (n=1) or jejunal
strangulation (n=1), and mean interval between admission
and colloid treatment was 15 hours. Horses qualified for
study enrolment based on plasma protein concentration
(19) and plasma albumin concentration (18). Following
randomization, age, weight, COP, plasma albumin, total
protein, PCV, and blood gas analytes did not differ
between the two treatment groups prior to colloid admin-
istration, as described in Table 1.
Adverse reactions were not observed with either colloid
treatment. When treatment groups were combined, mean
COP prior to administration was 11.0 mmHg [9.7 – 12.2
mmHg] and post colloid treatment was 13.2 mmHg
[12.0-14.7 mmHg]. Clinicopathologic effects of colloid
administration are described by treatment group in Table
1. COP was significantly increased with colloid treatment
Table 1 Summary of selected clinical and clinicopathologic variables of horses with naturally occuring gastrointestinal
disease within treatment groups prior to and following colloid administration. Results listed as mean and [95%
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(P<0.001) regardless of treatment group. This COP
increase was not significantly different between treatment
groups (P=0.051). Venous pH did not change signifi-
cantly with colloid treatment (P=0.226) and did not differ
between groups (P=0.866).
During remaining hospitalization, 1 horse in group 1
(hydroxyethyl starch in normal saline solution) and 3
horses in group 2 (hydroxyethyl starch in lactated ringers
solution) were treated with an additional 10 mL/kg dose
of hydroxyethyl starch in normal saline solution for per-
sistent signs associated with hypoproteinemia. In addi-
tion, 2 horses in each treatment group were treated with
4 – 10 mL/kg of intravenous commercial plasma.
Five of 10 horses in group 1 (hydroxyethyl starch in nor-
mal saline solution) and 7 of 10 horses in group 2 (hydro-
xyethyl starch in lactated ringers solution) survived to
hospital discharge. In addition, 8 horses in group 1 (hydro-
xyethyl starch in normal saline solution) and 9 horses in
group 2 (hydroxyethyl starch in lactated ringers solution)
developed complications during hospitalization. Complica-
tions observed included laminitis (n=4), DIC (1), jugular
thrombosis (2), fever (5), nasogastric reflux (4), rectal pro-
lapse (1), melena (3), peritonitis (2), endotoxemia (3), renal
failure (1), colic pain (10), persistent tachycardia or tachyp-
nea (7), incisional drainage or infection (3), and partial
incisional dehiscence (1). Survival (P=0.650) and develop-
ment of complications during hospitalization (P=1.000)
did not differ significantly between treatment groups.
Discussion
The results of the present study indicate that both
hydroxyethyl starch formulations evaluated increase
COP when used in the treatment of horses with low
colloid oncotic pressure due to hypoproteinemia. Col-
loid supplementation improved COP approximately
20%, regardless of the formulation used. However, col-
loid treatment did not result in COP values within the
equine normal range of 18-22 mmHg [7]. Venous pH
was not affected by colloid administration. Therefore, it
is presumed that type of colloid carrier fluid, normal sal-
ine versus lactate ringers solution, did not impact acid-
base parameters in this setting.
Jones, P.A. and colleagues encountered similar results
in measured COP after administration of 8-10ml/kg of
6% high molecular weight hydroxyethyl starch in 5
hypoproteinemic adult horses and 6 horses ≤1 year of
age [8]. In that study, there was a significant increase in
measured COP, a mean of 1.5 mmHg post-infusion
(13%), that persisted for 24 hours and returned to base-
line values at 48 hours [8]. Similar to the present study,
the increase in measured COP, although significant, did
not reach the normal values reported in healthy horses
[8]. The limited increase in COP observed in response
to both formulations of hydroxyethyl starch in the
present study, in addition to volume expansion, is com-
monly observed in diseased populations of humans [9].
In healthy horses administered 10mL/kg hydroxyethyl
starch, plasma volume expansion was increased approxi-
mately 17 or 19%, dependent on formulation, for up to
8 hours despite a sustained increase in COP for 24
hours [10]. The length of plasma volume treatment
effect following hydroxyethyl starch administration in
critically ill horses warrants further study.
While volume expansion effects are largely indepen-
dent of hydroxyethyl starch solution formulation, other
treatment effects are directly attributed to size, config-
uration, and carrier of these colloid solutions. Though
not observed acutely in the present study, treatment
with hydroxyethyl starch in saline vs balanced crystal-
loid solutions is more frequently associated with devel-
opment of hyperchloremic metabolic acidosis in
humans [4]. Hydroxyethyl starch suspended in
balanced electrolyte solution also has been shown to
preserve coagulation function, assessed by thromboe-
lastography, better than those in saline in humans
[11,12]. High molecular weight and molar substitution
hydroxyethyl starch solutions, such as those evaluated
in the present study and frequently used in treatment
of horses with hypoproteinemia, have greater adverse
effects on platelet function and other indices of coagu-
lation than lower moleular weight and molar substitu-
tion formulations [10,13,14]. Future studies performed
in the target population, critically ill horses, will com-
plement those evaluating newer generations of hydro-
xyethyl starch solutions in healthy animals and further
inform treatment decisions and monitoring in the dis-
eased population.
In the present study, COP was increased following
colloid treatment, but did not reach the normal range. It
is unknown whether a higher dose would have resulted
in a post-treatment COP value closer to the normal
range or whether it is necessary to target a specific COP
treatment goal in horses. Investigators evaluating 10, 20,
and 40 mL/kg doses of low molecular weight and molar
substitution hydroxyethyl starch solution in healthy
horses did not observe linear increases in duration of
COP elevation post infusion with dose, with significant
elevation of COP observed for 24, 6, and 48 hours
respectively [13]. A study in critically ill humans found
that risk of mortality due to low COP could be elimi-
nated by maintenance of a mean COP of >16 mmHg
with colloid treatment, despite values of COP persis-
tently below the normal range [15]. When combining
the colloid groups evaluated in the present study, the
mean pre-treatment COP value was 11 mmHg and
post-treatment was 13.2 mmHg. Both pre- and post-col-
loid treatment mean COP values were below 16 mmHg.
It is likely that the high case fatality rate (40%) observed
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was related to a combination of factors, namely illness
severity and low COP.
In the present study, a limited number of clinical cases,
with diverse disease etiology, were used to evaluate the
effects of hydroxyethylstarch administration. Further,
several horses required additional doses of colloid sup-
plementation during hospitalization and the impact of
such treatments is unknown. Serial measurements of
COP, PCV, and venous blood gas parameters may have
determined variability in parameter measurements over
time and further distinguished beneficial effects from
treatment. The outcome parameters evaluated were lim-
ited to COP, PCV, venous blood gas analysis, develop-
ment of complications, and short term survival to
hospital discharge. Inclusion of coagulation and long
term survival outcomes may have demonstrated differ-
ences between groups.
Conclusions
Based on the results of this preliminary clinical study,
hydroxyethyl starch in lactated ringers solution was at
least equivalent to hydroxyethyl starch in normal saline
solution. Further study is needed to determine how these
two products compare with regards to other outcome
measures and complications. Evaluation of the relative
effects of colloid formulation in horses with clinical dis-
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